Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT).
about
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromesDrug-eluting stents versus bare metal stents for angina or acute coronary syndromesSirolimus-eluting stents for treatment of in-stent restenosis: immediate and late resultsDrug-eluting stent: a review and updateAdjunctive intra-coronary imaging for the assessment of coronary artery diseasePercutaneous coronary intervention: recommendations for good practice and training.Fabrication of stents with endothelial function in vitro.Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centreTherapeutic potential of active stent coating.Gene therapy for cardiovascular angiogenesis.Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.Drug eluting stents in 2005.Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents.Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease.Drugs to suppress cough.Stents or surgery: the case for stents.Update on drug-eluting stents for prevention of restenosis.Efficacy and safety of drug-eluting stents: current best available evidence.Delivery of large biopharmaceuticals from cardiovascular stents: a reviewCurrent status of off-pump coronary artery bypass surgery.Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis.Associations of proteins relevant to MAPK signaling pathway (p38MAPK-1,HIF-1 and HO-1) with coronary lesion characteristics and prognosis of peri-menopausal women.Vascular Stem/Progenitor Cell Migration Induced by Smooth Muscle Cell-Derived Chemokine (C-C Motif) Ligand 2 and Chemokine (C-X-C motif) Ligand 1 Contributes to Neointima Formation.Delivery of paclitaxel from cobalt-chromium alloy surfaces without polymeric carriersIntravascular drug release kinetics dictate arterial drug deposition, retention, and distribution.Regulation of vascular smooth muscle cell growth: targeting the final common pathwayComparison of sirolimus-eluting, paclitaxel-eluting, and bare-metal stents in a patient with angina pectoris: histopathological autopsy findings of the third month.Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial.Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry.Toward High-Performance Coatings for Biomedical Devices: Study on Plasma-Deposited Fluorocarbon Films and Ageing in PBS.Late angiographic stent thrombosis: the LAST straw for drug-eluting stents?Disruptive technological advances in vascular access for dialysis: an overview.
P2860
Q24186681-12703882-AF30-444F-8B63-5EE6CA624040Q24235466-D5B91BD8-D078-4BFC-9311-1BB8E9E61C05Q28175715-4F098D7E-BBDA-4E42-BBE5-94AB719244E2Q28219254-2AFEE510-BC49-4C76-BF30-176C06E545B5Q30376274-806CEFC9-0548-4D1A-9446-159A848CA6F1Q30479477-D6251F3E-B1F5-440E-AF25-FB2BB3E47D3FQ33488585-E29C717D-A81D-4B42-826D-C967A7E936BBQ34024602-9C6DB721-B49C-4D1B-899F-A9E158F8EB9AQ35117070-A234E9B6-FEF0-4149-9E2B-0785A31567F3Q35164797-732E37C6-FF89-4CC4-937E-3871ECD67179Q35708574-BD11AA8E-B8E2-44A8-B0E9-89253B68C4ADQ35808313-63622E9A-C312-45FC-9245-0779A8CC5588Q35879094-D1B3587C-8D06-45E3-BBE8-D389E855FFD6Q35925484-D8FB0E8F-E491-4AE8-8989-778ECC894BA3Q35938663-E20AB4A2-97BF-41F9-8A2C-ACD545F58E49Q35945466-9E33C86E-887B-4387-A592-F26B10A7F70DQ36040853-130DA2B7-E235-40B3-8A37-C75801177A0AQ36360162-F92BFCA3-79CC-4E13-B24B-62C9E74B56ECQ36375853-B6591CF0-1A2F-4E09-A8A4-FD50B53567F8Q36639071-E09410B7-F2F4-450D-8099-983F7DBBDA6BQ36968009-95CE77BA-0A04-4137-AE6D-050718456041Q37125540-942F617F-E530-4EA6-A662-669BB54AEE45Q37374015-EF3D8C51-9F15-4EA2-BA76-441056EBF86BQ37400816-01DD9434-8174-4036-AD0D-52BDDB51C33FQ41109128-60AA42F2-230E-4914-AE5A-300AA881F6F2Q41562461-97941B35-1BE4-4A1D-8961-BE2D73D5A624Q42057757-4BED0BF6-73FC-4FC7-8905-25A69A10A708Q42411623-8E2FB00C-9D15-4C26-9C5C-B3959D383B4AQ43507024-665CD025-F27C-4492-81D1-324C94F97662Q45201019-75DE1189-2BFE-4154-A656-69617D2936B3Q46942290-A0D934FB-EDA9-4EC0-8097-3B098A2E82A2Q46982876-B0DFDDF6-4213-4811-A88A-0938D6C587EBQ47795262-AD366C07-4211-47BD-8952-0B0788AFD66EQ48213898-32BF98D2-8862-4025-AB34-EEB209E78F9F
P2860
Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Paclitaxel coating reduces in- ...... Stent Clinical Trial (ASPECT).
@en
Paclitaxel coating reduces in- ...... l-Eluting Stent Clinical Trial
@nl
type
label
Paclitaxel coating reduces in- ...... Stent Clinical Trial (ASPECT).
@en
Paclitaxel coating reduces in- ...... l-Eluting Stent Clinical Trial
@nl
prefLabel
Paclitaxel coating reduces in- ...... Stent Clinical Trial (ASPECT).
@en
Paclitaxel coating reduces in- ...... l-Eluting Stent Clinical Trial
@nl
P2093
P1433
P1476
Paclitaxel coating reduces in- ...... Stent Clinical Trial (ASPECT).
@en
P2093
ASian Paclitaxel-Eluting Stent Clinical Trial
Cheol Whan Lee
Duk-Hyun Kang
Gary S Mintz
Jae-Joong Kim
Jae-Kwan Song
Jong-Min Song
Ki-Hoon Han
Myeong-Ki Hong
Neal E Fearnot
P304
P356
10.1161/01.CIR.0000054163.42072.D4
P407
P577
2003-02-01T00:00:00Z